myasthenia gravis
Neurology · 2025–2025
2decisions
2medicines
2carried consumer input
44individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| efgartigimod alfa Treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody positive and symptomatic despite use of… | Mar 2025 | Recommended with restriction | 28 individuals Myasthenia Alliance Australia |
| ravulizumab Treatment of newly diagnosed and treatment-refractory patients with generalised myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody positive… | Mar 2025 | Recommended with restriction | 16 individuals Myasthenia Alliance Australia |
Who spoke
Myasthenia Alliance Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.